NM_006231.3:c.4735C>T (p.Arg1579Cys) is a missense variant in the C-terminal polymerase domain of POLE, distant from the exonuclease domain (residues 1-466) where established pathogenic missense variants cluster.¹ This variant is present at very low frequency in population databases: gnomAD v2.1 at 0.00319% (1/31,386 alleles), gnomAD v4.1 at 0.00050% (8/1,613,270 alleles), and absent from gnomAD-Canada, meeting PM2 at supporting strength.² Under the León-Castillo et al. 2020 custom POLE framework, this variant does not qualify for PM1 (not an exonuclease-domain hotspot), PS4 (not a recurrent pathogenic variant in endometrial carcinoma cohorts), PP3 (absent from supplementary in silico tables), or BP4 (absent from supplementary in silico tables).³ Computational predictors are mixed and do not converge on a pathogenic signal: REVEL 0.412 (intermediate), BayesDel 0.071 (benign-leaning), SpliceAI max delta 0.20 (borderline). PP3 and BP4 are not met.⁴ This variant is reported in ClinVar (VariationID 405672) as 'Uncertain significance' by three clinical laboratories. The associated publications (PMID:25394175, a cancer genetics referral guideline, and PMID:28492532, the Sherloc classification framework) do not provide variant-specific evidence for NM_006231.3:c.4735C>T.⁵ No functional studies, segregation data, de novo observations, or case-control studies are available for this variant. All remaining pathogenic criteria (PS1-PS5, PM1, PM5-PM6, PP1-PP5) and benign criteria (BA1, BS1-BS4, BP1-BP6) are either not met or not applicable.⁶ With only PM2_Supporting met, the overall classification is Uncertain Significance (VUS) per ACMG/AMP 2015 guidelines: insufficient evidence to classify as pathogenic or benign.⁷